Roche (SIX: RO, ROG; OTCQX: RHHBY) has extended its commitment to the World Federation of Hemophilia (WFH) Humanitarian Aid Program until the end of 2028. Roche’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to treatment.
Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
May 12, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022